Company Information
CIN
Status
Date of Incorporation
05 June 1989
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
598,820,400
Authorised Capital
650,000,000
Directors
Arvind Sadashiv Mokashi
Director/Designated Partner
over 2 years ago
over 2 years ago
Vinita Mayur Danait
Director/Designated Partner
over 2 years ago
over 2 years ago
Banwarilal Murlidhar Bawri
Director/Designated Partner
over 2 years ago
over 2 years ago
Lalit Kumar Singal
Manager/Secretary
over 2 years ago
over 2 years ago
Rajesh Kumar Mittal
Director/Designated Partner
over 2 years ago
over 2 years ago
Vijay Girdharilal Agarwal
Director/Designated Partner
almost 4 years ago
almost 4 years ago
Girdharilal Murlidhar Bawri
Director/Designated Partner
almost 4 years ago
almost 4 years ago
Rajendra Murlidhar Agarwal
Director/Designated Partner
almost 4 years ago
almost 4 years ago
Sanjay Rajdev
Director
over 10 years ago
over 10 years ago
Navrang Lal Tibrewal
Director
over 19 years ago
over 19 years ago
Vimal Chand Kothari
Director
over 19 years ago
over 19 years ago
Past Directors
Pradeep Vishwanath Gadge
Director
almost 5 years ago
almost 5 years ago
Mihir Bipin Shah
Director
over 9 years ago
over 9 years ago
Ashok Anant Mahashur
Director
over 10 years ago
over 10 years ago
Vinayak Vasudev Shirodkar
Cfo(kmp)
about 11 years ago
about 11 years ago
Suvarna Abhijeet Bhaskar
Company Secretary
almost 15 years ago
almost 15 years ago
Atul Kumar Shukla
Additional Director
over 18 years ago
over 18 years ago
Patents
The present invention provides a solid oral pharmaceutical composition comprising clopidogrel or pharmaceutically acceptable salt thereof, formulated using a mixture of solid and liquid excipient, along with at least one pharmaceutically acceptable excipient. The present invention also relates to a process for the p...
The invention relates to an oral extended release solid pharmaceutical composition of donepezil hydrochloride comprising at least one pH independent polymeric release retardant and one more pharmaceutically acceptable excipient. The invention also describes a process for preparation of donepezil hydrochloride extend...
The invention relates to an oral extended release pharmaceutical composition such as monolayer tablets of paracetamol comprising low viscosity polymeric release retardant and at least one pharmaceutically acceptable excipient. The invention further relates to paracetamol composition which exhibits unique dissolution...
The present invention relates to a process for the preparation of pharmaceutical formulation containing inclusion complex of cyclodextrin and an anti-inflammatory agent such as meloxicam. The cyclodextrin may be any suitable cyclodextrin such as substituted or unsubstituted beta cyclodextrin in ratios such as 1:1 up...
The invention provides a cost effective or economical process for the preparation compound of Formula II (impurity C) and its pharmaceutically acceptable salts and its use as a reference standard during the analysis of Ziprasidone hydrochloride prepared by any chemical process.
The present invention provides soft gel capsule formulation for oral administration comprising supersaturated matrix of therapeutically active drug or pharmaceutically acceptable salt thereof, formulated using a mixture of solubilizer, viscosity enhancing agent along with at least one pharmaceutically acceptable exc...
The present invention provides an improved process for the preparation of tetrazole of Valsartan by using catalytic amount of water in the reaction.
The present invention relates to a cost effective and industrially advantageous process for the isolation of Linezolid of Formula I substantially free from compounds of Formula II and III. The invention also relates to novel polymorphic Form M of Linezolid substantially free from Linezolid Form II, process for its p...
The present invention provides an extended release formulation comprising
therapeutically effective amount of cyclobenzaprine, at least one water soluble
polymeric release retardant, and at least one pharmaceutically acceptable excipient; optionally along with non-polymeric release retardant. The invention furth...
The present invention relates to a process for the preparation of storage stable amorphous atorvastatin calcium comprises treating atorvastatin calcium with aqueous ammonia solution and isolating storage stable amorphous atorvastatin calcium.
Disclosed herein is a process for preparing Cinacalcet hydrochloride, (R)-α-methyl-N-[3-[3-(trifluoromethyl) phenyl] propyl]-1-naphthalene methane hydrochloride via N-[1-(R)-(1-naphthyl ethyl]-3-[3-(trifluoromethyl) phenyl]-1-propanamide(X), a novel intermediate.
Pharmaceutical composition comprising a combination of a proton pump inhibitor, preferably rebeprazole sodium with domperidone for the treatment of GERD and other GI disorders are disclosed. Rabeprazole is in enteric coated form, while domperidone is in dual release forms of immediate and pH independent sutained rel...
The present invention describes the synthesis of gemifloxacin pivalate and process for its preparation.
The present invention relates to an efficient and scaleable synthetic process of N-[2-[4-(pivaloyloxy) phenylsulfonamido] benzoyl] glycine sodium salt tetrahydrate (sivelestat sodium).
The present invention discloses the process for the preparation of 5-Difluoromethoxy-2-[(3, 4-dimethoxy-2-pyridinyl)-methyl sulfinyl]-1-H-benzimidzole (Pantoprazole) having formula (I), The compound of formula I is prepared by subjecting respective 2-(2-pyridylmethylthio) benzimidazole compound to oxidation with ter...
The present invention relates to a process for the enantiomeric enrichment of Escitalopram. or pharmaceutically acceptable addition salts thereof. The process includes
a) precipitating Escitalopram as a salt of (-) isomer of optically active acid from a solution
of non-racemic Citalopram b) converting optically ac...
The present invention discloses a robust and reproducible method to prepare co-formulation of Lopinavir and Ritonavir which does not compromise with bioavailability of the drug.
The present invention relates to an improved process for the preparation of Rizatriptan and its pharmaceutically acceptable salts by reacting 4-(lH-l, 2, 4-triazole-1-yl methyl) phenyl hydrazine dihydrochloride with 4-N, N -dimethylamino-butyraldehyde diethyl acetal and purifying by using neutral alumina.
...
The present invention provides a simple and commercially viable process for the preparation of sildenafil citrate.
The present invention relates to a process for the preparation of trimebutine maleate having the structural Formula I.
The invention relates to an oral extended release solid pharmaceutical composition in the form of spheroids comprised of a therapeutically effective amount of venlafaxine hydrochloride, about 10 to 70% of low-substituted hydroxypropyl cellulose, microcrystalline cellulose or a mixture thereof and at least one more p...
The present invention relates to a stable oral pharmaceutical formulations comprising amorphous atorvastatin calcium. The atorvastatin formulation prepared according to the present invention involves use minimum amount of pH adjusting substance preferably below 5%, more preferably below 4% by the total weight of the...
A process for the preparation of thermodynamically stable atorvastatin in an amorphous form which comprises suspending atorvastatin calcium in a methanol solvent, filtering and distilling the solvent to afford thermodynamically stable atorvastatin calcium in an amorphous form.
The present invention relates to a process of preparing pure Telmisartan of structural formula I comprising the steps of: a) condensing 2-«-propyl-4-methyl-6-(i"-methylbenzimidazol-2"-yl)benzimidazole of structural formula II with a 4"-bromomethyl-biphenyl-2-carboxylic acid alkyl ester of structural formula V withou...
A process for preparing pure Famciclovir compound of formula I comprising reducing acetic acid 2-acetoxymethyl-4-(5-amino-7-chloro-imidazo[4,5-b]pyridin-3-yl)-butyl ester compound of formula IV in ether solvent by catalytic hydrogenation.
The present invention relates to an improved process for the preparation of valsartan of structural formula I by the use of novel intermediates of structural formula IX, X, XI, XII and XIII
The present invention relates to an improved and industrially advantageous process for the preparation of (5-methylpyridin-3-yl) methanol of Formula I, as shown in the accompanied drawings. This compound is a key intermediate for the synthesis of Rupatadine Fumarate, a potent dual antagonist of histamine and platele...
The present invention relates to a process for the preparation of irbesartan compound comprising reacting 4"-[(2-butyl-4-oxo-1, 3-diazaspiro [4.4] non-l-en-3-
yl) methyl] biphenyl-2-carbonitrile compound with sodium azide in the presence of organic base and sulfuric acid.
This invention relates to a novel improved process for the preparation of Amtolmetin Guacil, starting from N- benzyloxycarbonylglycine and & Sodium [l-methyl-5- (4-methylbenzoyl)-lH-pyrrol-2-yl] acetate,
The present invention provides a feasible and commercially viable process for the preparation of amtolmetin Guac...
The present invention relates to a process for the preparation of montelukast sodium salt. The process includes (a) reacting 2-(2-(3-(S)-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-hydroxypropyl)-phenyl-2-propanol of Formula II with diphenyl chloro phosphate to get a compound of Formula III; (b) condensing the compoun...
The present invention relates to extended release formulation of levetiracetam comprising hydrophobic rate controlling polymer preferably ethyl cellulose and prepared by simple wet granulation method using water and isopropyl alcohol mixture as a granulating fluid.
The present invention relates to a process for the preparation of Clopidogrel bisulfate crystalline Form 1, which is devoid of any contamination of Clopidogrel bisulfate crystalline Form 2.
The present invention relates to a purification process for removing montelukast sulphoxide impurity of formula II and montelukast styrene impurity of formula III up to below detection limit (Limit of detection = 0.1% w/w and Limit of quantitation =0.25% w/w) from montelukast and its pharmaceutically acceptable salt...
The present invention relates to a process for the preparation of quetiapine hemifumarate of structural formula I. The process comprising the steps of a) condensing silyl protecting dibenzo[b, ƒ][l,4]thiazepine of structural formula VII with piperazine to give a condensed product 1 l-piperizinyldibenzo[b, ƒ] [I, 4]t...
“A process for preparation of pharmaceutical composition containing a non-steroidal anti-inflammatory substance (NSAID) and a cyclodextrin.”
The present invention relates to a for the preparation of a pharmaceutical composition containing a non-steroidal anti-inflammatory substance (NSAID) such as valdecoxib and ...
Oral cefixime formulation with improved bioavailability and stability profile by employing combinations of inorganic alkalizing agent.
The present invention relates to a process for the preparation of montelukast sodium salt. The process includes (a) reacting 2-(2-3-(S)-(3-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-hydroxypropyl)- phenyl-2-propanol of Formula II with diphenyl chloro phosphate to get a compound of Formula III; (b) condensing the comp...
An improved and industrially feasible process for the preparation of 8-chloro-6, 11- dihydro-11-[1-[(methyl-3-pyridinyl) methyl]-4-piperidinylidene]-5H-benzo [5, 6] cyclohepta [1,2b] pyridine (rupatadine).
The invention describes a new process for the preparation of dimethyl fumarate. The process involves esterification of fumaric acid using methanol in the presence of acid catalysts such as poly phosphoric acid, hydrochloric acid and mixture there of. The highly pure crystalline dimethyl fumarate contains no genotoxi...
The present invention provides a solid pharmaceutical composition comprising taste-masked donepezil or pharmaceutically acceptable salt thereof, which dissolves or disintegrates in the oral cavity.
The present invention also relates to a process for the preparation of a taste-masked pharmaceutical composition comp...
The invention relates to topical pharmaceutical composition of luliconazole and/or a salt thereof, and methods of using such composition for the treatment or prevention of fungal skin infections such as tinea pedis, tinea cruris, tinea corporis, and a method of preparing such composition. The invention specifically ...
The invention relates to a topical gel pharmaceutical composition of amorolfine or pharmaceutically acceptable salts thereof, and methods of using such composition in treating fungal infections of nails and/or skin by topically administering such composition, and a method of preparing such composition. The invention...
This invention relates to beneficial pharmaceutical compositions for use in the treatment of pain and inflammation in mammalian organism, said composition comprising: (i) local skeletal muscle relaxant Cyclobenzaprine or its pharmaceutical acceptable salts and (ii) analgesic, non-steroidal anti inflammatory Diclofen...
A novel combination of Vitamin E, Fraxinus excelsior and/or N-acetyl-L cysteine (NAC) in a single unit dosage form for the prevention or treatment of non-alcoholic fatty liver disease (NAFLD).
The present invention relates to a pharmaceutical composition for oral administration comprising Isavuconazole with combination of surfactants and co-surfactants and other pharmaceutically acceptable excipients that provides rapid dissolution and enhanced absorption of the Isavuconazole.
The invention relates to a sustained release pharmaceutical composition comprising Vildagliptin or pharmaceutically acceptable salt thereof with one or more hydrophobic excipients as release retarding material, wherein hydrophobic excipients are selected from fatty acids, fatty alcohols and their esters or salts or ...
The present invention relates to a pharmaceutical composition comprising a combination of therapeutically effective amount of Erdosteine and a Bronchodilator; for the effective treatment, prevention and/or reduction of symptoms of respiratory disorders such as chronic and acute respiratory diseases and disorders lik...
Registered Trademarks
[Class : 5] Pharmaceutical, Medicinal And Veterinary Preparations
[Class : 5] Pharmaceutical, Medicinal And Veterinary Preparations
[Class : 5] Pharmaceutical, Medicinal And Veterinary Preparations
View +644 more Brands for Macleods Pharmaceuticals Ltd.
Charges
19 September 2013
Icici Bank Ltd.
2 Crore
19 September 2013
Icici Bank Ltd.
1 Crore
19 September 2013
Icici Bank Ltd.
2 Crore
19 September 2013
Icici Bank Ltd.
1 Crore
29 November 2006
Citi Bank N.a.
60 Crore
09 August 1990
State Bank Of India
64 Lak
22 March 1994
State Bank Of India
1 Crore
31 July 2021
Standard Chartered Bank
71 Crore
21 June 2021
Hdfc Bank Limited
59 Crore
26 April 2021
Axis Bank Limited
50 Crore
26 April 2021
Icici Bank Limited
91 Crore
07 September 2020
State Bank Of India
214 Crore
26 April 2021
Others
0
07 September 2020
State Bank Of India
0
31 July 2021
Standard Chartered Bank
0
21 June 2021
Hdfc Bank Limited
0
26 April 2021
Axis Bank Limited
0
19 September 2013
Icici Bank Ltd.
0
29 November 2006
Citi Bank N.a.
0
22 March 1994
State Bank Of India
0
19 September 2013
Icici Bank Ltd.
0
19 September 2013
Icici Bank Ltd.
0
19 September 2013
Icici Bank Ltd.
0
09 August 1990
State Bank Of India
0
26 April 2021
Others
0
07 September 2020
State Bank Of India
0
31 July 2021
Standard Chartered Bank
0
21 June 2021
Hdfc Bank Limited
0
26 April 2021
Axis Bank Limited
0
19 September 2013
Icici Bank Ltd.
0
29 November 2006
Citi Bank N.a.
0
22 March 1994
State Bank Of India
0
19 September 2013
Icici Bank Ltd.
0
19 September 2013
Icici Bank Ltd.
0
19 September 2013
Icici Bank Ltd.
0
09 August 1990
State Bank Of India
0
26 April 2021
Others
0
07 September 2020
State Bank Of India
0
31 July 2021
Standard Chartered Bank
0
21 June 2021
Hdfc Bank Limited
0
26 April 2021
Axis Bank Limited
0
19 September 2013
Icici Bank Ltd.
0
29 November 2006
Citi Bank N.a.
0
22 March 1994
State Bank Of India
0
19 September 2013
Icici Bank Ltd.
0
19 September 2013
Icici Bank Ltd.
0
19 September 2013
Icici Bank Ltd.
0
09 August 1990
State Bank Of India
0
Documents
Form MGT-14-07012021_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-29122020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-29122020
Form MSME FORM I-19112020_signed
Form PAS-6-27102020_signed
Optional Attachment-(1)-26102020
Form DPT-3-23102020-signed
Form MGT-14-02102020_signed
Form MGT-7-24092020_signed
Optional Attachment-(1)-23092020
Copy of MGT-8-23092020
List of share holders, debenture holders;-23092020
Form DPT-3-14092020-signed
Form MSME FORM I-14082020_signed
Form MR-1-11082020_signed
Form PAS-6-11082020_signed
Copy of board resolution-11082020
Optional Attachment-(1)-11082020
Copy of shareholders resolution-11082020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -11082020
Form MR-1-21072020_signed
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -21072020
Copy of board resolution-21072020
Copy of shareholders resolution-21072020
Form PAS-6-20072020_signed
Optional Attachment-(1)-20072020
Form MR-1-18072020_signed
Copy of board resolution-18072020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -18072020
Copy of shareholders resolution-18072020
